Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Here’s the correct link for the exceptional BTIG report
https://drive.google.com/file/d/17eIR1UoVzt5bIeXEGETl4bt_cKW0tc_o/view
here is what a real Research Report looks like:
https://smallpdf.com/pdf-reader?job=1618680978170
LifeMD responds to false accusations
https://finance.yahoo.com/amphtml/news/lifemd-responds-anonymous-short-report-113000025.html
We had a $.35 gain going until around 3:00 then shorts came in and drove price back down.
This only brings us closer to the end of available shares to short. I noticed strong buying, probably institutional judging from the size of the blocks this morning from 9:30 to 11:00 and then again from 2:00 to 2:45. They will be back tomorrow.
Yeah that's what happens during short assaults. When the stock rises suddenly there is lots for sale at much lower prices.
You are right.
Lots of shares for sale ... 8.90
I am a fundamentalist and I like what see in the next 3 years and beyond so time is in LONGs favor with all of this. This uncomfortable situation will bring more followers and will make the company stronger. That's what happens with great people, companies and things in general when there is high quality.
The decline has stopped despite continued small short sales today. Lots of incomplete short position info out today on several financial sites. At least 30% of trades were short sales over the last 3 weeks. That means at least 6 million shares are short. More than half of the float. If many of the s/h's either placed high priced sell orders or informed their brokers that they were not to lend their shares, we are probably getting very close to exhausting supply of shares that can be borrowed.
Also institutional ownership has been rising so with continued institutional buying and current shareholders feeling more secure in averaging down their basis we will see an upswing in price and maybe a short squeeze. About 4 years ago when LFMD was IMMD we had a short squeeze where in 1 day the price went from $.22 to $.94. May it happen again...from $9.00 to $40!
You are probably right, but I hope the law firms' investigators can pierce the veils and get to these bastards.
The jerk on this platform tries to seem clueless, but he knows better. I know who he is. He once was a shareholder who had to sell some years ago before the stock price began to flourish, in order to pay some debts. He not only lost money but has never been able to build a decent position. So now his posts are simply sour grapes. I am sorry for his bad fortune, but he is simply mean spirited when he gloats over the temporary misfortune of LFMD and its shareholders. But we will be vindicated. Don't forget Gamestop!
I can see that with a couple of Q reports and upward guidance. By the end of August.
Thanks
He is a class act he called me 2 nights in a row and was actually apolegetic. He doesn't want anyone to feel let down. He takes his role very seriously. In fact, his family and friends are significantly invested. This will be back above $30 very soon.
I found the Reddit page for LFMD. No Stress!
Happy: thanks for the update. Where did you post on Reddit?
I can vouch for Alex as we both talked with Justin last December. He’s a very upstanding gentleman. His passion and team-building skills and his commitment to shareholder value is stellar.
It’s unfortunate and unlikely though that this short firm will pay for the damaged they’ve caused to ignorant retail investors - like the one poster on this message board who is clueless.
Thanks for the heads up. I was thinking of calling Justin myself. I have talked to him a couple o times myself and another partner. I was telling my partner yesterday that since we spoke with him the first time last year he seemed honest and pro regulatory compliant, hence the delays in some of the projects. And also about all the new hiring, as soon as he had the opportunity, to oversee the whole operation. Regulatory, quality, financials, call center. Everything. The medical advisory board is impressive. He made it very clear, and several times, that customer service was at the heart of the future success in this type of business model.
Thanks again
Alex
Bought this morning some more @ $8.53. A few thousand more.
8$ ... was 30$ .... and your Happy??
The only clown is YOU for accepting the claims of an obviously sleazy anonymous group. The doc in question is still licensed to conduct telemedicine. He was charged with a practice, which though frowned upon , is quite common among busy docs. He signed blank prescription forms in his office. I have seen signed prescription forms on at least 2 occasions in the offices of 2 docs. So there is nothing to be concerned about here.
They use accredited physicians, licensed in all states where they practice. LFMD has 2 senior staff members overseeing medical quality and legal compliance. This management team is exceptional and does things right. WE are the victim of an unscrupulous group of scammers. Combat it by joining REddit and posting about this scam and the opportunity with LFMD
There are now at least 3 Major law firms investigating the fraudulent operations of this criminal short selling operation. I spoke with the CEO last night who called me (I have been a substantial shareholder for several years) to assure me that NONE OF THE CLAIMS were legitimate, that the company is doing very well, as reported previously, that several significant announcements are forthcoming that will clear up the truth and demonstrate the continued excellent performance of the company. In thousands and thousands of contacts with patients and customers, complaints about the subscription program are diminimus, actually in single digits.
Research Culper Research for yourselves and find out what a scam short selling program they are. They will not identify themselves or their sources and they literally hide so that they can avoid the SEC.
I joined Reddit and made a post describing the scam. We all should in order to get traction.
You would think these Clowns could contract with legit doctors !
What a disgrace ... it’s a very easy thing to do.
Poor management and zero oversight ???
oh my gosh ... we are single digits and falling fast ... we need a legit rescue !
The Connecticut suspension was to remain in place until the board could hold a hearing to determine his mental fitness to practice. Instead, Badii agreed to waive the hearing and accept the terms of a consent order which places his license on probation for two years, but allows him to provide telehealth services to patients.
https://www.nhregister.com/news/article/CT-med-board-allows-doctor-to-treat-patients-via-15954848.php
You took the words right out of my mouth. First thing I did was research this firm. It’s a shell that hides the identity of the owners. A total sham. The question is, how do we galvanize the Reddit folks to buy into every illegitimate short these firms initiate?
Culper Research is a sleazy short selling group that has made similar attempts with other rapidly rising firms. Their modus operandi is to start shorting to drive price down and then come out with a bogus research report to further push the price down so they can cover their previously developed short position. Notice the massive surge in last 2 days. Google them and you will find out that they are under investigation and have lawsuits against them They are considered fraudulent by legitimate financial firms. Cleanspark and CytoDyn are 2 recent targets of Culper Research. "Emerging Growth" Wed., April 14, has an expose on Culper Research that confirms what I have said.
Time to buy. Cause a short squeeze as these criminals attempt to cover their short positions. REMEMBER GAMESTOP!!!
Culper Research piece may explain the slide?
https://img1.wsimg.com/blobby/go/cc91fda7-4669-4d1b-81ce-a0b8d77f25ab/downloads/Culper_LFMD_4-14-2021.pdf?ver=1618406082207
This boat is sinking Happy ... and I’m not Happy about it ! They pumped it to 30$ and now it’s half that .
Plain and simple . It’s sinking fast
Only someone totally ignorant of business would post that. Your posts continue to demonstrate your lack of knowledge. Companies in rapid growth developmental stages never pay dividends or conduct buybacks which would be an unproductive use of their cash needed to fund the rapid growth. Buybacks, further, are a bogus manipulation of the market, which only someone totally ignorant such as you would fall for. You are not a shareholder, just a griper who has missed the LFMD boat.
Hope and prayer methods ... How bout company buy backs, dividends, and old fashioned demand ???
The recent price declines and selling is Short Selling. There is a very thin float and with so much short selling over the last 2 weeks, it will cease very soon. Shorts must cover their borrowed shares and they will fuel an upsurge. Further there is demand waiting on the sidelines as buyers are fearful of trying to catch a falling knife. Indeed, many, like myself who bought at the $20 level have gotten nicked. IMO this will reverse around mid month when Q1 revenues are announced. From what I have heard revenue growth is actually accelerating. Such positive news will spook short sellers and motivate investors.
The recent price declines and selling is Short Selling. There is a very thin float and with so much short selling over the last 2 weeks, it will cease very soon. Shorts must cover their borrowed shares and they will fuel an upsurge. Further there is demand waiting on the sidelines as buyers are fearful of trying to catch a falling knife. Indeed, many, like myself who bought in the $20 level have gotten nicked. IMO this will reverse around mid month when Q
30$ a share ??? Looks about half that here
LifeMD Launches NavaMD™ Adding Direct-to-Patient Clinical Skincare Services to its Portfolio of Personalized Telehealth Brands
More content below
LFMD
-0.75%
LifeMD, Inc.
Wed, April 7, 2021, 8:31 AM
More content below
LFMD
-0.75%
The brand launch into tele-dermatology adds further portfolio diversification into exciting and fast-growing area of patient healthcare
NEW YORK, April 07, 2021 (GLOBE NEWSWIRE) -- LifeMD, Inc. (the “Company”) (NASDAQ: LFMD), a leading direct-to-patient telehealth company, today announced the successful launch of NavaMD™. The NavaMD website went live at the end of the first quarter of fiscal 2021 and is the Company’s personalized tele-dermatology brand and clinic, offering services to patients across all 50 states.
Justin Schreiber, Chairman and CEO commented, “We are pleased to bring the NavaMD brand to life in 2021, as this will be LifeMD’s third successful brand launch in four years. We are an early mover in the $40 billion-dollar high growth direct-to-patient tele-dermatology space and are well-positioned to grow market share. By empowering patients seeking telehealth services, we feel that LifeMD is best positioned to actively bring about a sea change in both the convenience and accessibility by which patients receive personalized services and medications when needed. As such, we remain focused on refining customer acquisition strategies and building a de-risked brand portfolio that addresses low risk, massively underpenetrated and addressable markets such as the NavaMD clinical skincare offering.”
“By focusing on fast growing, therapeutic areas with high unmet needs, whose treatments are proven to be safe, we are creating the best runway for unrivaled growth in telehealth customer acquisition, recurring revenues and return on shareholder value,” mentioned Stefan Galluppi, Chief Technology Officer.
NavaMD’s services will be available to any patient seeking dermatology services. Service offerings include the diagnosis and treatment of prevalent skin conditions such as acne, rosacea, hyperpigmentation, signs of aging, and other prevalent skin conditions. NavaMD’s customer acquisition strategy will be primarily set to growing its female customer base, fully supported by best-in-class direct response marketing, social media, and influencer campaigns. Online medical treatment and services will be rendered through LifeMD’s network of U.S. licensed physicians, pharmacies, and, if appropriate, prescription oral and compounded topical medications to treat many common dermatological conditions. In addition to the brand’s telemedicine offerings, NavaMD’s proprietary products leverage intellectual property and proprietary formulations licensed from Restorsea, a leading medical grade skincare technology platform. NavaMD is the first external provider to offer Restorsea’s patented medical-grade over-the-counter products for treating these prevalent skin conditions.
Like other LifeMD brands, NavaMD tele-dermatology services is highly personalized, powered by a proprietary technology stack. The engagement with patients is seamless and is driven by a simple three-step customer journey consisting of:
Completing a free consultation: whereby a questionnaire and patient photo is submitted for review.
Getting prescribed a custom formulated treatment regimen: NavaMD’s licensed U.S. doctors, and clinicians then work to design a custom prescription skincare treatment. A quick and convenient checkout process powered by LifeMD’s telehealth platform fills a prescription.
The patient receives a personalized treatment by mail: LifeMD’s pharmacy services prepares and delivers a customer’s custom prescription treatment on a monthly recurring basis or as often as needed.
About LifeMD
LifeMD Launches NavaMD™ Adding Direct-to-Patient Clinical Skincare Services to its Portfolio of Personalized Telehealth Brands
More content below
LFMD
-0.75%
LifeMD, Inc.
Wed, April 7, 2021, 8:31 AM
More content below
LFMD
-0.75%
The brand launch into tele-dermatology adds further portfolio diversification into exciting and fast-growing area of patient healthcare
NEW YORK, April 07, 2021 (GLOBE NEWSWIRE) -- LifeMD, Inc. (the “Company”) (NASDAQ: LFMD), a leading direct-to-patient telehealth company, today announced the successful launch of NavaMD™. The NavaMD website went live at the end of the first quarter of fiscal 2021 and is the Company’s personalized tele-dermatology brand and clinic, offering services to patients across all 50 states.
Justin Schreiber, Chairman and CEO commented, “We are pleased to bring the NavaMD brand to life in 2021, as this will be LifeMD’s third successful brand launch in four years. We are an early mover in the $40 billion-dollar high growth direct-to-patient tele-dermatology space and are well-positioned to grow market share. By empowering patients seeking telehealth services, we feel that LifeMD is best positioned to actively bring about a sea change in both the convenience and accessibility by which patients receive personalized services and medications when needed. As such, we remain focused on refining customer acquisition strategies and building a de-risked brand portfolio that addresses low risk, massively underpenetrated and addressable markets such as the NavaMD clinical skincare offering.”
“By focusing on fast growing, therapeutic areas with high unmet needs, whose treatments are proven to be safe, we are creating the best runway for unrivaled growth in telehealth customer acquisition, recurring revenues and return on shareholder value,” mentioned Stefan Galluppi, Chief Technology Officer.
NavaMD’s services will be available to any patient seeking dermatology services. Service offerings include the diagnosis and treatment of prevalent skin conditions such as acne, rosacea, hyperpigmentation, signs of aging, and other prevalent skin conditions. NavaMD’s customer acquisition strategy will be primarily set to growing its female customer base, fully supported by best-in-class direct response marketing, social media, and influencer campaigns. Online medical treatment and services will be rendered through LifeMD’s network of U.S. licensed physicians, pharmacies, and, if appropriate, prescription oral and compounded topical medications to treat many common dermatological conditions. In addition to the brand’s telemedicine offerings, NavaMD’s proprietary products leverage intellectual property and proprietary formulations licensed from Restorsea, a leading medical grade skincare technology platform. NavaMD is the first external provider to offer Restorsea’s patented medical-grade over-the-counter products for treating these prevalent skin conditions.
Like other LifeMD brands, NavaMD tele-dermatology services is highly personalized, powered by a proprietary technology stack. The engagement with patients is seamless and is driven by a simple three-step customer journey consisting of:
Completing a free consultation: whereby a questionnaire and patient photo is submitted for review.
Getting prescribed a custom formulated treatment regimen: NavaMD’s licensed U.S. doctors, and clinicians then work to design a custom prescription skincare treatment. A quick and convenient checkout process powered by LifeMD’s telehealth platform fills a prescription.
The patient receives a personalized treatment by mail: LifeMD’s pharmacy services prepares and delivers a customer’s custom prescription treatment on a monthly recurring basis or as often as needed.
About LifeMD
Earnings Update: Here's Why Analysts Just Lifted Their LifeMD, Inc. (NASDAQ:LFMD) Price Target To US$37.50
More content below
Simply Wall St
Sat, April 3, 2021, 4:00 AM
There's been a notable change in appetite for LifeMD, Inc. (NASDAQ:LFMD) shares in the week since its annual report, with the stock down 10% to US$17.26. Revenues were in line with expectations, at US$37m, while statutory losses ballooned to US$4.44 per share. This is an important time for investors, as they can track a company's performance in its report, look at what experts are forecasting for next year, and see if there has been any change to expectations for the business. We thought readers would find it interesting to see the analysts latest (statutory) post-earnings forecasts for next year.
Check out our latest analysis for LifeMD
If you think anyone cares about your "gambling" on this stock, you are a bigger moron than we thought. We do not need luck, as it has nothing to do with the performance of LFMD. The longs have Justin and his team.
FYI I have been buying small amounts of shares (10,000 shares at a clip) and selling call options (20 strike price ) for the last few months. My stock had been called away each time. I then rebuy the following week .Earnings are out this Monday night so today I sold 100 naked 20 puts at 2.80. I'm back gambling on this stock.
Good luck to us all including Louis Silver. LOL
True. Growth is awesome.
By the end of next week (Friday) the green line in the Revenue Graph (Mid page , right) is going to look VERY LONG compared to the other ones from previous years. And probably the same will happen next year around the same time.
https://finance.yahoo.com/quote/LFMD/financials?p=LFMD
FROM ANOTHER BOARD:
Let’s take a detailed peek under the hood of LifeMD:
$LFMD Revenues:
q4’19 $4M
q1’20 $4.3M (+$0.3M, 7.5%)
q2’20 $9.1M (+$4.8M, 112%)
q3’20 $11M (+$1.9M, 21%)
q4’20 $13.6M (+$2.6M, 23.6%)
q1’21 $17.1M (+$3.5M, 26.7%)
q2’21 $21.8M (+$4.7M, 27.5%)**
** = my extrapolation
And this is all while shifting the revenue mix from 68% recurring-subscription to 85% recurring-subscription, quite obviously a better model.
Removing the large one-time Covid bump from q2’20, we have revenue growth that is *accelerating*, that is to say the derivative of growth (the growth of the growth) is rising, the flywheel is working, and we can see how easily the company can get to $90M revenue with their *current* product mix. We’re still very early in the S-curve. This is incredibly powerful.
That $90M doesn’t even include the launch of NavaMD or LifeMD GP Concierge services this year. Not saying it will happen, but there is a case to be made for $100M in revenue this year.
Then, if the growth rate stopped accelerating (best to be conservative in projections), and even regressed to, let’s say, 20% Q/Q for all 4 quarters in 2022, that’s $207M in 2022 revenues. This enterprise is valued at $460M at the moment. Let that sink in.
Let’s say growth rate then fell to 10% Q/Q in 2023 (it’s harder to maintain those growth rates with size). That’s $303M revenue in ‘23. Then an anemic 5% Q/Q growth rate in ‘24 for conservatism’s sake (there are consulting firms projecting 15% annual YoY growth in telehealth through 2027).
That’s, conservatively, $370M in revenue in 2024. At 80% gross margin. That’s $300M gross profit. Holy smokes that is a lot of capital generated in a year to fuel further growth for the latter half of the decade. Or a tasty buyout by Ro or Hims at 8x Gross Profit, a $2.4B purchase (5x return from here for $LFMD shareholders).
Anyway, if you’re reading this, you’re invited to my beach house in 2026 ???? ???? Only 5 years away!
Less
Everything is for now...hopefully things improve next week...
Wow this thing is plummeting down ?!
AMZN is now offering Telemedicine to its employees. Wouldn't they like to have a really robust platform to offer Telemedicine and prescription and non-prescription medications to everyone? Just thinking....Bezos is very acquisitive and buy vs build is a no brainer here. Two to two and a half billion in AMZN stock is pocket change for them. BUT $80 to $100/share for us.
I think they saw the rapid runup and decided the risk was worth it. Obviously they did not expect the superlative execution od the LFMD team.
I never understood why short sellers try to short growing companies like this. I get shorting trash bios. Not this stock though. They deserve to get burned honestly.
Today's trading was a battle of the Short Sellers and the Investors. We traded up to $21.40. Then around 11:30 through 12:30 the short sellers entered and sold about 250,000 shares. We rebounded to $20.90 but then around 2:30 the shorts entered again and sold another 200,0R0 shares short, pushing us down to $20.00. BUT the buyers, perhaps many new eyes as a result of the Roth Capital conference this week. came back in big at the end to push us up to $20.49, a 3.3% gain.
The short sellers are almost in a panic. They know they are facing the 10K and Q1 revenues and maybe estimates and the LFMD conference call at month's end. They may be fighting a losing battle to keep the price down.
Understood, Happy. Now in hindsight, I realize I jumped the gun. Not sure I want that responsibility either.
Followers
|
14
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
157
|
Created
|
03/17/21
|
Type
|
Free
|
Moderators |
"Liquidity Evaluation
As of September 30, 2021, the Company has an accumulated deficit approximating $122.9 million and has experienced significant losses from its operations. Although the Company is showing significant positive revenue trends, the Company expects to incur further losses through the end of 2022."
"Reverse Stock Split
On October 9, 2020, the Company filed a Certificate of Amendment to its Articles of Incorporation with the Secretary of State of Delaware (the “Amendment”) in order to effectuate a 1-for-5 reverse stock split of the Company’s issued and outstanding shares of common stock (the “Reverse Split” or “Split”). The Reverse Split was approved by the Financial Industry Regulatory Authority (FINRA) and became effective in the market on October 14, 2020."
"On February 11, 2021, the Company consummated the closing of a private placement offering (the “February 2021 Offering”), whereby pursuant to the securities purchase agreement (the “February 2021 Purchase Agreement”) entered into by the Company and certain accredited investors on February 11, 2021 the Investors purchased 608,696 shares of the Company’s common stock par value $0.01 per share at a purchase price of $23.00per share for aggregate gross proceeds of approximately $14.0 million (the “Purchase Price”). The Purchase Price was funded on the closing date and resulted in net proceeds to the Company of approximately $13.5 million after deducting fees payable to the placement agent and other estimated offering expenses payable by the Company. The Company intends to use the net proceeds to fund growth initiatives, as well as for general corporate purposes.
On June 1, 2021, the Company entered into a securities purchase agreement (the “Purchase Agreement”) with a financial institution (the “Purchaser”), pursuant to which the Company sold and issued: (i) a senior secured redeemable debenture (the “Debenture”) in the aggregate principal amount of $15.0 million (the “Aggregate Principal Amount”), and (ii) warrants to purchase up to an aggregate of 1,500,000 shares of the Company’s common stock at an exercise price of $12.00 per share (the “Warrant”) of which 500,000 warrants were issued to the Purchaser upon closing with the remaining 1,000,000 warrants only issued to the Purchaser in increments of 500,000 if the Debenture remains outstanding for twelve and twenty four months, respectively, following the closing date of the Purchase Agreement. The Warrant has a term of three years, and the Debenture has a maturity date of three years. The Debenture may be paid fully or in part by the Company at any time prior to maturity without penalty to the Company. The Company received gross proceeds of $15.0 million and intends to use such proceeds for working capital, growth investment and general corporate purposes. In October 2021, the Company used a portion of the net proceeds from the October 4, 2021 Preferred and Common Stock Offerings noted below to pay the $15.0 million outstanding on the June 1, 2021 Purchase Agreement.
On June 8, 2021, the Company filed a shelf registration statement on Form S-3 under the Securities Act of 1933, or “Securities Act”, which was declared effective on June 22, 2021 (the “2021 Shelf”). Under the 2021 Shelf at the time of effectiveness, the Company had the ability to raise up to $150 million by selling common stock, preferred stock, debt securities, warrants and units. In conjunction with the 2021 Shelf, the Company also entered into an At Market Issuance Sales Agreement (the “ATM Sales Agreement”) with B. Riley Securities, Inc. (“B. Riley”) and Cantor Fitzgerald & Co. (“Cantor”, and collectively the “Agents”) relating to the sale of its common stock. In accordance with the terms of the ATM Sales Agreement, the Company may, but is not obligated to, offer and sell, from time to time, shares of common stock having an aggregate offering price of up to $60million, through or to the Agents, acting as agent or principal. Sales of common stock, if any, will be made by any method permitted that is deemed an “at the market offering” as defined in Rule 415 under the Securities Act. The Company intends to use any net proceeds from the sale of securities for our operations and for other general corporate purposes, including, but not limited to, capital expenditures, general working capital and possible future acquisitions. There were 70,786 shares of common stock sold under the ATM Sales Agreement as of September 30, 2021 and net proceeds received were $493,481. The Company had approximately $59.5 million available under the ATM Sales Agreement and $90 million available under the 2021 Shelf as of September 30, 2021.
In September 2021, the Company entered into two underwriting agreements (the “Preferred Underwriting Agreement” and “the Common Underwriting Agreement”) with B. Riley Securities, Inc. (“B.Riley”). Pursuant to the Preferred Underwriting Agreement, the Company agreed to sell 1,400,000 shares of its 8.875% Series A Cumulative Perpetual Preferred Stock, par value $0.0001 per share, (the “Series A Preferred Stock”) at a public offering price of $25.00 per share, prior to deducting underwriting discounts and commissions and estimated offering expenses (the “Preferred Stock Offering”). In addition, the company granted the underwriters an option to purchase up to an additional 210,000 shares of Series A Preferred Stock within 30 days. Under the Common Underwriting Agreement, the Company agreed to sell to B. Riley 3,833,334 shares of common stock (including 500,000 shares pursuant to B. Riley’s option) (the “Common Shares”), par value $0.01 per share, of the Company at a public offering price of $6.00 per share of common stock, prior to deducting underwriting discounts and commissions and estimated offering expenses (the “Common Stock Offering”). The Preferred Stock Offering and Common Stock Offering collectively referred to as the “Offerings”, closed on October 4, 2021. Net proceeds after deducting the underwriting discounts and commissions, the structuring fee and estimated offering expenses payable by the Company, but before repayment of debt, from the Offerings was approximately $55.3 million. The Company used a portion of the net proceeds to pay the $15.0 million outstanding on the June 1, 2021 Purchase Agreement and intends to use the remaining net proceeds to fund the segregated dividend account, for working capital and general corporate purposes including, but not limited to, new patient customer acquisition expenses and capital expenditures.
The Company will pay cumulative distributions on the Series A Preferred Stock, from the date of original issuance, in the amount of $2.21875 per share each year, which is equivalent to 8.875% of the $25.00 liquidation preference per share. Dividends on the Series A Preferred Stock will be payable quarterly in arrears, on or about the 15th day of January, April, July and October of each year. The first dividend on the Series A Preferred Stock sold in this offering will be paid on or about January 15, 2022."
"
COVID-19 Vaccine Mandate
We are making preparations to comply with a rule issued by the Occupational Safety and Health Administration (“OSHA”) to ensure that our employees are fully vaccinated against COVID-19 by January 4th or that they test negative for COVID-19 at least once per week. Employees must receive time off to get vaccinated and sick leave to recover from any side effects. Any unvaccinated employees must wear face coverings while at work. We are in the process of assessing the financial and staffing impact of these requirements."
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |